United Therapeutics' Unituxin Disappoints In SCLC
Impact Likely Minimal On Company's Growth
Executive Summary
Targeting gangliosides expressed on SCLC tumors has been explored by United Therapeutics in the Phase II/III DISTINCT study, but top-line results show no effect on overall survival.
You may also be interested in...
Merck & Co's Keytruda Disappoints In Small-Cell Lung Cancer
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.
Missed BEAT Removes Tough Sell For United Therapeutics
The Phase III failure of esuberaprost combined with Tyvaso in pulmonary arterial hypertension has prompted United Therapeutics to stop developing a therapy that was already facing an uphill battle for potentially meager returns.
Bristol’s Checkmate-331 Failure Not Likely To Endanger SCLC Labeling For Opdivo
Opdivo failed to meet an overall survival endpoint in a Phase III confirmatory study in small-cell lung cancer. But several analysts think Bristol will keep the SCLC labeling obtained in August due to lack of treatment options for these patients.